ReCode Therapeutics
Powering the next wave of genetic medicines through superior delivery
Powering the next wave of genetic medicines through superior delivery
ReCode Therapeutics is a clinical-stage genetic medicines company with a focus on powering the next wave of mRNA and gene correction therapeutics through superior delivery. Established in 2015 and headquartered in the United States, the company utilizes its selective organ targeting (SORT) lipid nanoparticle (LNP) platform to enable precise delivery to target organs and cells beyond the liver. In its latest funding round in September 2023, ReCode Therapeutics secured a $50.00M Series B investment from a group of prominent investors including Amgen Ventures, MPM Capital, OrbiMed, Osage University Partners, EcoR1 Capital, Leaps by Bayer, Sanofi Ventures, Solasta Ventures, Bioluminescence Ventures, and Pfizer Venture Investments. This substantial investment affirms the confidence of key players in the industry in the potential of ReCode's innovative approach to genetic medicines delivery.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $50.00M | 10 |
|
19 Sep 2023 |
| Venture Round | $10.00M | 1 |
|
10 Jan 2023 |
| Series B | $120.00M | 5 |
|
29 Jun 2022 |
| Series B | $80.00M | 10 |
|
21 Oct 2021 |
| Series A | $80.00M | 5 |
|
26 Mar 2020 |
No recent news or press coverage available for ReCode Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
